Are HCPs Discussing CGM With Those in Need?
What's the Story?
Abundant clinical trial data and real-world evidence shows that starting CGM is beneficial for anyone with diabetes, regardless of their treatment regimen. Put simply, CGM should become the standard of care.
So, it is surprising to see that 78% of people with type 2 diabetes (PWT2D) in the dQ&A Patient Voice USA Q1 Data Pool state that they have not discussed CGM at all with their healthcare provider (HCP). See Chart 1 below.
Physicians might be hesitant to modify diabetes therapy for those patients doing well. But the majority of those not at goal still report that they haven’t talked about CGM with their HCP – see Chart 2.
Will patients act independently of their HCP? Our data suggests that only 15% of PWT2D will adjust their diabetes management regimen without consulting an HCP – see Chart 3.
The bottom line: A combination of clinical inertia and reimbursement issues is slowing down the penetration of CGM into the type 2 market. For more data and analysis, contact dQ&A.
.png)
Are HCPs Ready to Discuss CGM
With Their Patients?
The new Q1 Data Pool for dQ&A’s USA Patient Voice Data Service is now available. The following charts are a tiny fraction of the the insights and analysis encompassed in this Data Service.
Chart 1: HCPs and CGM
Most type 2 patients have not discussed using a CGM with their HCP. This is even more pronounced for those patients not using insulin.
Having discussed CGM with non-users, HCPs do not recommend a sensor more than half the time, which may be hindering adoption.
Recent ADA guidance recommends CGM for people with T2D who take insulin.
Chart 2: CGM by A1c
About half of people with T2D in the USA haven’t reached the recommended goal of A1c≤7%. Presumably they would be good candidates for CGM.
Although HCPs seem to discuss CGM a little more frequently with non-users who have A1c>8%, the main takeaway is that HCPs are not having the conversation often enough.
Chart 3: Actions Taken
Broadly speaking, people with T2D are not very likely to make independent changes to their diabetes therapy when they notice their management is not going well.
If this result applies equally to CGM, then the responsibility is on HCPs to drive faster adoption of CGM.
Karen
Creative, Up-beat Moderator/Interviewer
"Insights I draw from our amazing panelists influence our client's smart decisions and directly improve life for very people I get to interview! How great is that?!”
Trevor
Mixed-Methods Research Expert. Multiple Published Papers.
"As someone with T1D, I'm grateful our work directly impacts devices and therapies”
Christianne
Data Services Architect. Career Research Guru.
“I have been working with dQ&A for over ten years, 100% focused on diabetes. I so love contributing to those mission-critical decisions.”
Phin
VP, Research Services. Structures big data to drive analysis and insight.
“It's a real privilege to work with data that can make such a significant difference”
Kim
10 Years on the Client Side. Delivers Actionable Insights
“At dQ&A I’m surrounded by seasoned researchers and compassionate individuals, united in our mission to make life better for people living with diabetes”
Phyllisa
Patient Advocate. Manages Content for People With Diabetes
“For the first time in my career, I don't deal with diabetes stigma in the workplace.”
The Need for Greater Access
and Awareness
Contact us to further discuss HCPs and CGM, including additional data and insights. Furthermore, you can tap into more information via our USA Patient Voice Data Service. This data snack is only a small portion of the insights and analysis offered by this Data Service.
Do You Have Questions
About Diabetes Research?
This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.
